The FDA granted approval for Journavx after clinical trials demonstrated its effectiveness in post-surgical pain relief ...
The new drug type targets pathways in the peripheral nervous system before pain signals reach the brain, potentially lowering ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
The FDA approves suzetrigine, a non-opioid pain medication, offering a safer alternative to opioids for pain management, ...
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...
A new type of non-opioid painkiller, aimed at treating short-term pain in adults, has been approved by the US Food and Drug ...
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of opioids.
The U.S. Food and Drug Administration (FDA) on Thursday approved Journavx, the first new class of pain medication in more ...
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...